



PTO/SB/08 (09-06)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Approved for use through 03/31/2007. OMB 0651-0031

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**Date Submitted: **JUN 23 2009**
(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/567,328
Filing Date	8/6/2004
First Named Inventor	Makoto SAWADA
Art Unit	1649
Examiner Name	Kimberly BALLARD
Attorney Docket Number	084335-0201

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1	WO 03/009881 A2	02/06/2003	Imarx Therapeutics, Inc.		
	F2	WO 03/020751 A2	03/13/2003	King's College London		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	F3	Supplementary European Search Report mailed April 8, 2009, in European Patent Application EP 06783020), 4 pages.	
	F4	BODER et al., "Yeast surface display for screening combinatorial polypeptide libraries," Nature Biotechnology, June 1, 1997, 15:553-557.	
	F5	EGLETON et al., "Transport of Opioid Peptides into the Central Nervous System," Journal of Pharmaceutical Sciences, November 1998, 87(11):1433-1439.	
	F6	KIM et al., "Human neural stem cells genetically modified for brain repair in neurological disorders," Neuropathology: Official Journal of the Japanese Society of Neuropathology, September 2004, 24(3):159-171.	
	F7	KONDO et al., "Yeast cell-surface display-applications of molecular display," Applied Microbiology and Biotechnology, March 1, 2004, 64(1):28-40.	
	F8	LAACKONEN et al., "A tumor-homing peptide with a targeting specificity related to lymphatic vessels," Nature Medicine, June 10, 2002, 8(7):751-755.	
	F9	LAACKONEN et al., "Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells," Proc. Natl. Acad. Sci., June 22, 2004, 101(25):9381-9386.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>JUN 23 2009</u> <i>(use as many sheets as necessary)</i>				Application Number	10/567,328
				Filing Date	8/6/2004
				First Named Inventor	Makoto SAWADA
				Art Unit	1649
				Examiner Name	Kimberly BALLARD
Sheet	2	of	2	Attorney Docket Number	084335-0201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	F10	MAKAR et al., "Brain-derived neurotrophic factor (BDNF) gene delivery into the CNS using bone marrow cells as vehicles in mice," Neuroscience Letters, February 17, 2004, 356:215-219.	
	F11	PIWKO et al., "Localization and Pharmacological Characterization of Somatostatin Recognition Sites in the Human Cerebellum," Neuropharmacology, June 1996, 35(6):713-723.	

Examiner Signature	/Kimberly Ballard/	Date Considered	03/15/2010
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.